| Code | CSB-RA011875MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Efalizumab, targeting ITGAL (Integrin Subunit Alpha L), also known as CD11a or LFA-1 alpha chain. ITGAL combines with CD18 to form lymphocyte function-associated antigen-1 (LFA-1), a critical integrin expressed on leukocytes that mediates cell-cell interactions through binding to ICAM-1, ICAM-2, and ICAM-3. This interaction plays an essential role in immune cell adhesion, migration, and T-cell activation. ITGAL is implicated in various inflammatory and autoimmune conditions, including psoriasis, multiple sclerosis, and transplant rejection, making it an important target for immunological research.
Efalizumab was a humanized IgG1 monoclonal antibody previously approved for moderate-to-severe plaque psoriasis that functioned by blocking LFA-1/ICAM-1 interactions, thereby inhibiting T-cell activation and trafficking to inflammatory sites. This biosimilar antibody provides researchers with a valuable tool for investigating leukocyte adhesion mechanisms, T-cell mediated immune responses, and inflammatory disease pathways in preclinical studies.
There are currently no reviews for this product.